Research Analysts’ Weekly Ratings Updates for Oruka Therapeutics (ORKA)

Oruka Therapeutics (NASDAQ: ORKA) recently received a number of ratings updates from brokerages and research firms:

• 1/13/2026 – Oruka Therapeutics had its price target raised by analysts at Wedbush from $42.00 to $45.00. They now have an “outperform” rating on the stock.
• 1/12/2026 – Oruka Therapeutics had its price target raised by analysts at BTIG Research from $63.00 to $73.00. They now have a “buy” rating on the stock.
• 1/7/2026 – Oruka Therapeutics is now covered by analysts at UBS Group AG. They set a “buy” rating and a $50.00 price target on the stock.
• 1/7/2026 – Oruka Therapeutics is now covered by analysts at UBS Group AG. They set a “buy” rating and a $50.00 price target on the stock.
• 12/18/2025 – Oruka Therapeutics is now covered by analysts at Piper Sandler. They set an “overweight” rating and a $75.00 price target on the stock.
• 12/18/2025 – Oruka Therapeutics is now covered by analysts at Piper Sandler. They set an “overweight” rating and a $75.00 price target on the stock.

Insider Activity

In related news, insider Joana Goncalves sold 7,000 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $31.81, for a total value of $222,670.00. Following the completion of the sale, the insider directly owned 1,518 shares of the company’s stock, valued at approximately $48,287.58. This represents a 82.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 24.69% of the company’s stock.

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.